Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.




This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

April 28, 2008

A Non Epo Product for Anemia of Chemotherapy? Will this dog hunt?

Analysis of: Oral PBI-1402 Demonstrates Significant Activity in Chemeotherapy-Induced Anemia Phase II Clinical Trial | www.pipelinereview.com
This analysis is solely the work of the author. It has not been edited or endorsed by GLG.
Analysis By:
Kenneth Algazy, MD, Clinical Professor of Medicine , University of Pennsylvania School of Medicine - CCKenneth Algazy, MD 
Clinical Professor of Medicine , University of Pennsylvania School of Medicine - CC
Implications: This non erythropoietin (Epo) product will raise hemoglobin levels and decrease the need for transfusions.

Analysis:  BUT, will this drug produce the same problem that Epo products do, namely strokes, coronary artery problems and tumor growth?? Approval will have a rather high bar to jump unless they convince the FDA that the different mechanism of action makes a difference.

Other Analyses of the Same Source Article:

Report a Concern

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics